Rainier Acquisition Corp 8-K filed 2026-09-11
- Accession
- 0001104659-26-107095
- Cik
- 2147219
- Company name
- Rainier Acquisition Corp
- Date filed
- 2026-09-11
- Form
- 8-K
- Index url
- https://www.sec.gov/Archives/edgar/data/2147219/000110465926107095/0001104659-26-107095-index.htm
- Txt url
- https://www.sec.gov/Archives/edgar/data/2147219/0001104659-26-107095.txt
Plain-English summary
Rainier Acquisition Corp filed this Form 8-K on 2026-09-11 under Item 8.01, Other Events. It announces that, commencing on September 14, 2026, holders of the units sold in its initial public offering may elect to trade the Class A ordinary shares and warrants in those units separately. Each unit consists of one Class A ordinary share, par value $0.0001 per share, and one-quarter of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share for $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation, and only whole warrants will trade.
The separated shares and warrants will begin trading on the Nasdaq Capital Market on September 15, 2026 under the symbols "RNAQ" and "RNAQW," respectively. Units that are not separated will continue to trade under "RNAQU." To separate units, holders need their brokers to contact Continental Stock Transfer & Trust Company, the company's transfer agent. The units began trading on Nasdaq on August 27, 2026.
The attached press release, Exhibit 99.1, gives context on the offering. The IPO, including full exercise of the underwriter's over-allotment option, totaled 8,625,000 Units and generated gross proceeds of $86,250,000, before underwriting discounts and offering expenses. An aggregate of $86,250,000 ($10.00 per Unit) was placed in the trust account. Chardan Capital Markets LLC acted as sole book-running manager. The company's SEC classification is SIC 6770, Blank Checks. It describes itself as a special purpose acquisition company that intends to focus its search on the global life sciences industries, although it will not limit the search to any particular industry or region. Chief Executive Officer Gbola Amusa, M.D., CFA signed the filing, and Guy Barudin is Chief Financial Officer.
The filing does not name any business combination target. Trading prices for the units, shares or warrants are not in the filing. The dollar amounts of underwriting discounts and offering expenses are also not in the filing excerpt.
Based on: form, company_name, date_filed, text, sec:entity:2147219.sic, sec:entity:2147219.sic_description